Migraine Relief
- Product NDC
- 63868-316
- 11-digit product format
- 638680316
- Labeler code
- 63868
- Product ID
- 63868-316_ee299f62-f505-5e30-e053-2995a90a3c41
- Type
- HUMAN OTC DRUG
- Nonproprietary name
- ACETAMINOPHEN, ASPIRIN and CAFFEINE
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- CHAIN DRUG MARKETING ASSOCIATION INC
- Application
- ANDA214039
- Marketing category
- ANDA
- Marketing start
- 2022-05-05
- Marketing end
- 0000-00-00
- Substance
- ACETAMINOPHEN; ASPIRIN; CAFFEINE
- Active strength
- 250 mg/1; mg/1; mg/1
- Pharmacologic classes
- Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [EPC], Nonsteroidal Anti-inflammatory Drug [EPC], Platelet Aggregation Inhibitor [EPC], Xanthines [CS]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
DailyMed Dashboard NDC Coverage#
NDC, Dashboard title, SPL version table| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|
| 63868-316 | MIGRAINE RELIEF (ACETAMINOPHEN, ASPIRIN AND CAFFEINE) TABLET [CHAIN DRUG MARKETING ASSOCIATION INC] | 3 | Legacy NDC | 20241013_4ec0f9e7-a533-4084-a03a-24c25132435a.zip |
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 63868-316-24 | 63868031624 | 1 BOTTLE, PLASTIC in 1 CARTON (63868-316-24) > 24 TABLET in 1 BOTTLE, PLASTIC | 2022-05-05 | 0000-00-00 | No | No | Current |